Poor results halt trial of arterial disease drug

08/31/2005 | Yahoo!

Toronto-based Vasogen announced an early end to a Phase III trial of its drug Celacade because results showed it was not effective in treating leg pain associated with arterial disease. The company said there were no indications of safety concerns, but the absence of a "sufficiently strong efficacy signal" prompted an early end to the trial.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ